Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096460 · ClinicalTrials.gov registry record · Phase 2
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00096460 is a Phase 2 study that was terminated before completion, run by Medical College of Wisconsin. The registered enrollment target is 30 participants.
The verdict
NCT00096460, a Phase 2 study, was terminated before completion, sponsored by Medical College of Wisconsin.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study is designed as a Phase II/III, multi-center trial, comparing two transplant strategies to determine whether non-myeloablative allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will improve long-term progression-free survival compared to autologous HSCT. Recipients will be biologically assigned to the appropriate treatment arm depending on the availability of a Human Leukocyte Antigen (HLA) matched sibling.
Interventions
- DRUG Filgrastim
- DRUG Cyclophosphamide and Rituximab
- RADIATION Chemotherapy or Radiation therapy
- DRUG Non-myeloablative Conditioning regimen
- PROCEDURE Allogeneic transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-08 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096460
The ClinicalTrials.gov registry entry for NCT00096460 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Filgrastim is the first listed.
NCT00096460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096460 about?
NCT00096460 is a clinical study titled "Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)". This study is designed as a Phase II/III, multi-center trial, comparing two transplant strategies to determine whether non-myeloablative allogeneic Hematopoietic Stem Cell Transplantation (HSCT) will improve long-term progression-free survival compared to autologous HSCT. Recipients will be biologic...
What is the current status of trial NCT00096460?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2004-08. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00096460?
The interventions under investigation include: Filgrastim (DRUG), Cyclophosphamide and Rituximab (DRUG), Chemotherapy or Radiation therapy (RADIATION), Non-myeloablative Conditioning regimen (DRUG), Allogeneic transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00096460?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.